[Cardiac safety of cinitapride].
Mearín
Fermín
F
Plazas
María Josep
MJ
Mas
Marta
M
Heras
Joan
J
D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000503:physiopathology; D001189:Aryl Hydrocarbon Hydroxylases / Q000378:metabolism; D001549:Benzamides / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D020117:Cisapride / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use; D065727:Cytochrome P-450 CYP2C8; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D004347:Drug Interactions; D004415:Dyspepsia / Q000188:drug therapy; D004562:Electrocardiography; D005765:Gastrointestinal Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000493:pharmacokinetics; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D058828:Serotonin 5-HT4 Receptor Agonists / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
D001549:Benzamides; D005765:Gastrointestinal Agents; D058830:Serotonin 5-HT2 Receptor Antagonists; D058828:Serotonin 5-HT4 Receptor Agonists; D001189:Aryl Hydrocarbon Hydroxylases; C450259:CYP2C8 protein, human; D065727:Cytochrome P-450 CYP2C8; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; C045316:cinitapride; D007654:Ketoconazole; D020117:Cisapride